Neurosense Therapeutics is trading at $0.43 (17% down) in after-hours trading as the sharp move appears driven by low-liquidity volatility rather than a fresh catalyst.
- The decline follows an 11.4% gain during the regular session on August 4, where the stock closed at $0.52.
- There have been no new company-specific news or SEC filings released after the market close to explain the price reversal.
- The move follows an already choppy week for the stock, with the current drop likely exacerbated by the volatile nature of extended-hours trading.